EMA starts safety-related review of obesity drug

The EMA has started a review of drugs containing substance amfepramone, which is typically used to dampen appetites as a treatment for obesity.
Photo: Rob Acket/EMA
Photo: Rob Acket/EMA
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Following a request from the Romanian medicines agency, the European Medicines Agency (EMA) has started reviewing the substance amfepramone, which is an ingredient in several drugs used for treating obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading